Treatment of Locally Advanced/Metastatic Colorectal Cancer
Search for other papers by Alan P. Venook in
Current site
Google Scholar
PubMed
Search for other papers by Christopher G. Willett in
Current site
Google Scholar
PubMed
Few treatment advances have been observed in recent years for the treatment of advanced colorectal cancer (CRC). The goal remains to find approaches beyond FOLFOX and bevacizumab that will prolong remission. Immunotherapy for patients with microsatellite instability–high tumors represents progress, but this is a very small subset and approximately 30% of patients will not experience response. In locally advanced CRC, good long-term outcomes and manageable toxicity are being achieved with contemporary treatment strategies. Total neoadjuvant therapy, which incorporates induction or consolidation chemotherapy, has improved the treatment of patients with rectal cancer and is now a standard of care, although optimal sequencing is still being debated. Nonoperative management is an emerging option for sphincter preservation, and ongoing studies are evaluating the omission of radiation in select patients.
Disclosures: Dr. Venook has disclosed serving as a scientific advisor for Amgen Inc., Genentech, Inc., Merck & Co., Inc., and Roche Laboratories, Inc. Dr. Willett has disclosed no relevant financial relationships.
© 2019-2024 National Comprehensive Cancer Network